Another group of researchers isolated two MHC class II-restricted TCRs from melanoma patients after MAGE-A3 vaccination, both of which recognize the same MAGE-A3243-258 peptide (KKLLTQHFVQENYLEY), supporting a previous hypothesis that genetically modified MAGE-3/HLA-DPB1*04:01 CD4+ T cells could lead to cancer patient regression. This evidence concerns the gene MAGEA3 and cancer.